5-Fluorouracil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency

Cancer Letters

Volumn 249, Issue 2, 2007, Pages 271-282

  Boisdron Celle, M ^a   Remaud, G ^a   Traore, S ^a   Poirier, A L ^a   Gamelin, L ^a   Morel, A ^a   Gamelin, E ^a  

^a CENTRE PAUL PAPIN   (France)

Author keywords

5 Fluorouracil; Deficiency; Dihydropyrimidine dehydrogenase; Fluoropyrimidines; Single nucleotide polymorphism; Toxicity

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; DIHYDROURACIL; FLUOROURACIL; FOLINIC ACID; URACIL;

ADULT; AGED; ARTICLE; CAUCASIAN; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIARRHEA; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; ENZYME DEFICIENCY; EPIGENETICS; FEMALE; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; PRIORITY JOURNAL; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; GENETIC SCREENING; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; URACIL;

EID: 33947416573     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.09.006     Document Type: Article

References (35)

1. Ezzeldin H., and Diasio R. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin. Colorectal Cancer 4 (2004) 181-189
2. de Gramont A., Bosset J.F., Milan C., et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a french intergroup study. J. Clin. Oncol. 15 (1997) 808-815
3. Andre T., Colin P., Louvet C., Gamelin E., Bouche O., and Achille E. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J. Clin. Oncol. 21 (2003) 2896-2903
4. Diasio R.B., and Johnson M.R. Dihydropyrimidine dehydrogenase: its role in 5-Fluorouracil clinical toxicity and tumor resistance. Clin. Cancer Res. 5 (1999) 2672-2673
5. Etienne M.C., Lagrange J.L., Dassonville O., et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J. Clin. Oncol. 12 (1994) 2248-2253
6. Lu Z., Zhang R., and Diasio R.B. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res. 53 (1993) 5433-5438
7. Tuchman M., Stoeckeler J.S., Kiang D.T., et al. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N. Engl. J. Med. 313 (1985) 245-249
8. Diasio R.B., Beavers T.L., and Carpenter J.T. Familial deficiency of dihydropyrimidine dehydrogenase (biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity). J. Clin. Invest. 81 (1988) 47-51
9. Gamelin E., Boisdron-Celle M., Delva R., et al. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J. Clin. Oncol. 16 (1998) 1470-1478
10. Gamelin E.C., Danquechin-Dorval E.M., Dumesnil Y., et al. Relationship between 5-fluorouracil dose-intensity and therapeutic response in patients with advanced colorectal cancer receiving 5-FU containing infusional therapy. Cancer 77 (1996) 441-451
11. A.H. Van Gennip, E.J. Van Bree-Blom, S.K. Wadman, et al., HPLC of urinary pyrimidines for the evaluation of primary and secondary abnormalities of pyrimidine metabolism. in: Hawk G.L. (Ed.), Biological Biomedical Applications of Liquid Chromatography, III. New York and Basel, Marcel Dekker Inc., 1982, pp 285-296.
12. Gamelin E., Boisdron-Celle M., Guerin Meyer V., et al. and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J. Clin. Oncol. 17 (1999) 1105-1110
13. Jiang H., Lu J., and Ji J. Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels. Br. J. Pharmacol. 141 (2004) 616-623
14. Fleming R., Milano G., Thyss A., et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res. 52 (1992) 2899-2902
15. Johnson M.R., Yan J., Shao L., et al. Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. J. Chromatogr. 696 (1997) 183-191
16. Van Kuilenburg A.B., Abreu R., and Van Gennip A. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Ann. Clin. Biochem. 40 (2003) 41-45
17. Mc Leod H.L., Collie-Duguid E.S.R., Vrecken P., et al. Pharmacogenetics 8 (1998) 455-459
18. Van Kuilenburg A.B.P., Muller E.W., Haasjes J., et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-Fluorouracil: frequency of the common IVS14 + 1G > A mutation causing DPD deficiency. Clin. Cancer Res. 7 (2001) 1149-1153
19. Collie-Duguid E.S.R., Etienne M.C., Milano G., et al. Known variant DPYD allelas do not explain DPD deficiency in cancer patients. Pharmacogenetics 10 (2000) 217-223
20. 13C] dihydrouracil. Clin. Cancer Res. 12 (2006) 549-555
21. Gamelin E., Boisdron-Celle M., Turcant A., Allain P., and Robert J. Rapid and sensitive HPLC analysis of halogenopyrimidines in plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 695 (1997) 409-416
22. Remaud G., Boisdron-Celle M., Hameline C., Morel A., and Gamelin E. An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 823 (2005) 98-107
23. Rouits E., Boisdron-Celle M., Dumont A., Guerin O., Morel A., and Gamelin E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin. Cancer Res. 10 (2004) 5151-5159
24. de Gramont A., Bosset J.F., Milan C., et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J. Clin. Oncol. 15 (1997) 808-815
25. Barbado M., Preisser L., Boisdron-Celle M., Verriele V., Lorimier G., Gamelin E., and Morel A. Tumor quantification of several fluoropyrimidines resistance gene expression with a unique quantitative RT-PCR method. Implications for pretherapeutic determination of tumor resistance phenotype. Cancer Lett. 242 (2006) 168-179
26. Van Kuilenburg A.B.P., Meinsma R., Zoetekouw L., et al. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14 + 1G > A mutation. Int. J. Cancer 101 (2002) 253-258
27. Van Kuilenburg A.B.P., Haasjes J., Van Gennip H., et al. Clinical implication of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-Fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin. Cancer Res. 6 (2000) 4705-4712
28. Mattison L., Johnson M.R., and Diasio R. A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms. Pharmacogenetics 12 (2002) 133-144
29. Vreken P., Van Kuilenburg A.B., Meinsma R., et al. Identification of a four-base deletion (delTCAT296-299) in the dihydropyrimidine dehydrogenase gene with variable clinical expression. Hum. Genet. 100 (1997) 263-265
30. Kouwaki M., Hamajima N., Sumi S., et al. Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a japanese patient with 5-Fluorouracil toxicity. Clin. Cancer Res. 4 (1998) 2999-3004
31. Vreken P., Van Kuilenburg A.B., Meinsma R., et al. Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W. Hum. Genet. 101 (1997) 333-338
32. Van Kuilenburg A.B., Haasjes J., Van Gennip H., et al. Clinical implication of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-Fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin. Cancer Res. 6 (2000) 4705-4712
33. Collie-Duguid E., Johnston S.J., Powrie R.H., et al. Cloning and initial characterization of the human DPYD gene promoter. Biochem. Biophys. Res. Commun. 271 (2000) 28-35
34. Alderborn A., Kristofferson A., and Hammerling U. Determination of single-nucleotide polymorphism by real-time pyrophosphate DNA sequencing. Genome Res. (2000) 1249-1258
35. Ronaghi M. Pyrosequencing sheds light on DNA sequencing. Genome. Res. 11 (2001) 3-11